Needham Maintains Buy on AtriCure, Lowers Price Target to $44
Needham Maintains Buy on AtriCure, Lowers Price Target to $44
Needham維持對AtriCure的買入,將目標股價下調至44美元
Needham analyst Mike Matson maintains AtriCure (NASDAQ:ATRC) with a Buy and lowers the price target from $49 to $44.
尼德姆分析師邁克·馬特森維持AtriCure(納斯達克股票代碼:ATRC)的買入並將目標股價從49美元下調至44美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。